FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)

View source ↗

Summary

FDA approved a supplemental application for CellCept (mycophenolate mofetil hydrochloride) submitted by Genentech, Inc., influencing labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Transplant Rejection
• Kidney Transplant Rejection
• Liver Transplant Rejection

Drugs mentioned

• CELLCEPT (mycophenolate mofetil hydrochloride)

Snippet

SUPPL AP for CELLCEPT (MYCOPHENOLATE MOFETIL HYDROCHLORIDE)